The Wall Street Journal – April 27, 2018
The new therapies deliver gene or gene altered cells to tackle some of the hardest to treat diseases, including in children. They come in at a high price: Novartis AG listed it’s newly approved self therapy for cancer at $475,000.
Genetically based, new forms of caregiving,
May greatly inflate “the cost of living.”
May greatly inflate “the cost of living.”